Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2025-06-01 Legal Proceedings Report
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Update on US legal proceeding with TherapeuticsMD Inc 1
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated 2 June 2025 regarding an update on a US legal proceeding involving Mayne Pharma and TherapeuticsMD. It details the filing of a complaint and a motion to dismiss, describing the nature of the legal dispute and damages sought. There are no financial statements, management discussion, or detailed financial data present. The document is a legal proceeding update rather than a full legal report or audit. It fits the category of Legal Proceedings Report (LTR) as it provides an update on significant lawsuits involving the company.
2025-06-01 English
Change in substantial holding 6 pages 294.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under Corporations Law Section 671B. It details changes in voting power and relevant interests of UBS Group AG and its related bodies corporate in Mayne Pharma Group Limited. The document includes specifics about share purchases and sales, nature of interests, and associations. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it does not fit other categories such as director dealings or capital changes. Therefore, the correct classification is MRQ with high confidence.
2025-06-01 English
Change in substantial holding 81 pages 4.6MB
Major Shareholding Notification Classification · 100% confidence The document is an ASX Form 604, which is a Notice of change of interests of a substantial holder under the Corporations Act 2001 Section 671B. It details changes in voting power and relevant interests of The Goldman Sachs Group, Inc. and its subsidiaries in Mayne Pharma Group Limited. The document includes extensive annexures listing subsidiaries, securities lending agreements, and detailed transactions affecting shareholdings. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is lengthy and contains detailed data on share transactions and holdings, not just an announcement or summary, confirming it is the actual notification filing rather than a report publication announcement or regulatory filing. Therefore, the correct classification is MRQ with high confidence.
2025-05-26 English
Change in substantial holding 6 pages 274.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under Corporations Law Section 671B. It details changes in voting power and relevant interests of UBS Group AG and its related bodies corporate in Mayne Pharma Group Limited. The document includes specifics about share transactions, voting rights, and associations, typical of a major shareholding notification. There is no indication of financial statements, management commentary, or other report types. The document is not an announcement of a report but a regulatory filing about shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2025-05-26 English
Response to ASX Aware Letter 5 pages 512.0KB
Regulatory Filings Classification · 95% confidence The document is a letter from ASX Compliance to Mayne Pharma Group Limited regarding a compliance query about continuous disclosure obligations under ASX Listing Rules, specifically Listing Rule 3.1. It discusses the company's response to a price query and the disclosure of an FDA Untitled Letter related to a scheme of arrangement with Cosette Pharmaceuticals. The letter requests detailed explanations and confirmations from the company about compliance with disclosure rules and the basis for informing the bidder but not the market. The document is correspondence between a regulatory body (ASX) and the company, focusing on regulatory compliance and disclosure matters. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a report, announcement of voting results, or a presentation. It is a regulatory inquiry and response letter, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2025-05-21 English
Update on Scheme with Cosette 2 pages 127.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 21 May 2025 regarding an update on a scheme implementation deed (SID) between Mayne Pharma and Cosette Pharmaceuticals. It discusses the status of the scheme, a notice of material adverse change, and the parties' positions and obligations under the SID. The content focuses on the progress and legal/contractual aspects of a proposed acquisition transaction rather than financial results, earnings, or detailed financial statements. There is no indication that this is a full merger proxy statement or tender offer filing (which would be MA or TAR), but rather an update on the scheme process and related negotiations. The document is not a full annual or interim report, earnings release, nor a regulatory certification. It fits best as a Capital/Financing Update (CAP) because it relates to a financing transaction (acquisition scheme) and updates shareholders on the status and negotiations of that transaction.
2025-05-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.